Leustatin is a noun that refers to a medication used in the treatment of chronic lymphocytic leukemia (CLL). It is a brand name for the drug Cladribine, which belongs to a class of medications called purine analogues.
Leustatin works by interfering with the growth and division of cancer cells, which slows down or stops their growth and replication. CLL is a type of cancer that affects the white blood cells, specifically the lymphocytes. It is a slow-progressing cancer that primarily affects older adults.
This medication is usually administered intravenously, either as a short infusion or as a continuous infusion over several days. It is typically given in cycles, with breaks in between to allow the body to recover. The dosage and frequency of Leustatin may vary depending on various factors, such as the patient's overall health, response to treatment, and other medications they are taking.
Common side effects of Leustatin may include nausea, vomiting, diarrhea, loss of appetite, fatigue, and a decreased number of blood cells. Less common but more serious side effects may include infections, bleeding, kidney problems, and an increased risk of developing other cancers.
It is important to note that the use of Leustatin should be closely monitored by a healthcare professional experienced in the treatment of CLL. They will assess the potential benefits and risks of the medication based on the individual's condition and overall health.
